Semax (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Dosing is subcutaneous and morning only. Semax is mildly activating, and dosing after early afternoon disrupts sleep, so any second dose stays before 1 to 2 PM. Breakdown products retain partial activity for 20 to 24 hours, which is why a morning injection covers the working day. Cycling is mandatory rather than optional: 10 to 14 days on and 2 to 3 days off prevents receptor desensitization and doubles as a check on whether the compound is still doing anything, and after 2 to 4 cycles a 1 to 2 week break follows. Effects build over 3 to 5 days as gene expression shifts, with full effects peaking during days 7 to 14 of each cycle. At 10 mg/mL every dose in the protocol falls under 10 units, so a syringe marked to 30 units reads far more accurately than a full 100 unit barrel; injections go into subcutaneous tissue with sites rotated across abdomen, thighs, and upper arms.

Results Timeline

Sequence described in the research record. Individual response varies.

• Days 1 to 5: assessment phase at 200 mcg, with subtle improvements typically reported at 2 to 3 days as gene expression begins to shift.
• Day 6 onward: the standard 300 to 400 mcg range, where focus, task initiation, and mental clarity build.
• Days 7 to 14: full effects peak, and cognitive stamina through the afternoon is most apparent.
• End of each cycle: 2 to 3 days off to reverse TrkB desensitization and confirm the compound is still working.
• After 2 to 4 cycles: 1 to 2 weeks off before the next block.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe: 200 mcg = 2 units, 300 mcg = 3 units, 400 mcg = 4 units, 600 mcg = 6 units, 800 mcg = 8 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C, use within 30 days, and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Protect from light; wrap vials in foil or store in an opaque container. A 10 mg vial reconstituted with 1.0 mL holds 100 units, about 25 days of dosing at 400 mcg per day, which fits inside the 30 day window.

Supplies Needed

Planning is based on cycles of 10 to 14 days on at 300 to 400 mcg per day, morning only, which works out to about 2.8 mg per week during an on block at 400 mcg.

Peptide Vials (Semax, 10 mg vial):

• Two cycles, roughly 28 dosing days at 400 mcg per day, total about 11.2 mg and call for 2 vials; four cycles, roughly 56 dosing days, total about 22.4 mg and call for 3 vials. High-demand blocks at 600 to 800 mcg consume vials faster, so budget about 50 percent more.

Insulin Syringes (U-100):

• Per week on a single morning dose: 7 syringes (U-100, with 30 unit markings preferred because every dose falls under 10 units).
• Per 14 day cycle: about 14 syringes on a single morning dose, or about 28 when the dose is split into an early and a late morning injection.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 1.0 mL, so one 10 mL bottle of bacteriostatic water covers 10 vials, far more than a four cycle run requires.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site.
• Per 14 day cycle: about 28 swabs on a single daily dose, or about 56 when split; one 100 count box covers two cycles.

Important Notes

Practical considerations for consistency and safety.

• Morning dosing only. Late dosing disrupts sleep, so every dose stays before 1 to 2 PM, and a split schedule places the second injection in the late morning rather than the afternoon.
• Cycling is mandatory. Receptor desensitization is the failure mode of continuous dosing: without breaks the same dose stops working, and with breaks sensitivity resets. The pattern is 10 to 14 days on, 2 to 3 days off, then 1 to 2 weeks off after 2 to 4 cycles.
• Starting at 200 mcg for 3 to 5 days establishes a baseline response. The target is the minimum effective dose, not the maximum tolerated one, and effects build over days rather than minutes: subtle changes at 2 to 3 days, peak focus and clarity at days 7 to 14.
• Grumpiness and irritability at higher doses or during the comedown is the most common community-reported pattern, and it is the cue to reduce the dose or pair with Selank. Headache or head pressure becomes more frequent above 600 mcg per day. Hair loss is reported anecdotally in nootropic forums but remains clinically unconfirmed across decades of Russian pharmaceutical surveillance.
• Stacking partners named in the master sheet are Selank (the standard pairing, offsetting activation with anxiolytic balance), Pinealon as a neuroprotective foundation, P21 for structural neurogenesis, and NAD+ for cellular energy support during cognitive recovery. Variants differ in stability rather than active molecule: N-Acetyl Semax Amidate lasts 4 to 8 hours against 2 to 4 for unmodified Semax, and Adamax lasts 6 to 12 hours and is the most stimulating. Contraindications are pregnancy or breastfeeding, active cardiovascular disease, and a history of seizures, with caution in bipolar disorder and in polypharmacy involving psychoactive substances.
• Regulatory Note: Semax has been registered as a pharmaceutical in Russia since 1994 and holds no Western regulatory approval. No Western randomized controlled trials exist, since the molecule is unpatentable and unattractive to commercial sponsors, so the evidence base is Russian clinical literature. The master sheet does not record a WADA classification for this compound. Supplied for research purposes only, not for human consumption.

How This Works

Semax is a synthetic ACTH(4-10) analog stabilized with a C-terminal Pro-Gly-Pro tail that strips out the parent molecule's hormonal effects while making the peptide resistant to enzymatic degradation. Its primary mechanism is BDNF/TrkB upregulation: it increases hippocampal BDNF mRNA expression and TrkB receptor density, driving synaptic potentiation, dendritic spine formation, and neuronal survival. Direct human confirmation comes from a 110 patient post-stroke study in which Semax raised plasma BDNF regardless of rehabilitation timing, with higher levels correlating to faster functional recovery. Secondary mechanisms include enhanced dopamine and serotonin turnover in prefrontal circuits, which improves signal quality without stimulant behavioral patterns, enkephalinase inhibition that preserves endogenous stress-buffering peptides, HPA axis buffering with no change in baseline cortisol but roughly 29 to 34 percent reduction under acute stress and prevention of adrenal hypertrophy under chronic stress, and a coordinated anti-inflammatory gene expression shift with reduced IL-8 and CRP alongside elevated IL-10 and TGF-beta1 in stroke patients. The delayed onset and the mandatory cycling both follow directly from that mechanism: gene expression changes take days to appear, and persistent TrkB activation triggers a receptor desensitization that off-periods reverse.

Benefits & Side Effects

Observations from the published record.

• Focus and clarity are the most consistently reported benefits. The community descriptor is clarity, meaning reduced mental static, rather than stimulant-style activation, and it shows up as easier task initiation, sustained attention, and less procrastination.
• Working memory and mental flexibility improved on formal cognitive testing in Russian clinical studies of chronic cerebrovascular disease, alongside gains in attention and short-term memory.
• Cognitive stamina: the typical afternoon fade is reported to disappear or arrive later, a combined product of stronger circuits, optimized dopamine handling, and reduced inflammatory drag.
• Neuroprotection carries the strongest evidence base. A meta-analysis of Russian stroke trials found that 12 to 18 mg per day of intranasal Semax accelerated neurological recovery by 4 to 7 days against controls, and a 3 year follow-up of 120 chronic cerebrovascular patients showed 2.5 times the recovery at 1 year and 3 times at 3 years.
• Stress buffering: cortisol falls under acute stress without baseline suppression, supporting performance under pressure.
• Side effects are dose-linked and mostly mild: occasional injection site irritation answered by site rotation, headache or head pressure more frequent above 600 mcg per day, agitation or overstimulation at higher doses, sleep disruption when dosed too late, irritability at higher doses or during the comedown, and roughly 7 percent nasal irritation or dryness on the intranasal route. No dependency or tolerance is documented with proper cycling, since receptor desensitization is reversible adaptation rather than dependence, and the safety profile has stayed clean across decades of Russian pharmaceutical surveillance with no documented serious adverse events at therapeutic doses.

Lifestyle Factors

Complementary strategies for best outcomes.

• Sleep of 7 to 9 hours is the foundation, and morning-only dosing exists in part to protect sleep architecture.
• Aerobic exercise reinforces BDNF signaling and neuroplastic adaptation through the same pathway Semax targets.
• Cognitive training during cycles determines what gets consolidated. Semax creates the conditions for adaptation; deliberate practice and demanding work decide what is built.
• Stress management, omega-3 fatty acids, B-vitamins, and an antioxidant-rich diet support BDNF synthesis and neural membrane integrity. Concurrent stimulant escalation works against the protocol, since Semax is not a stimulant replacement and stacking it indiscriminately with high-dose caffeine or amphetamines defeats the purpose.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Eremin KO et al. BDNF/TrkB upregulation by Semax in hippocampus (Brain Res, 2006).
2. Polunin GS et al. 110-patient post-stroke BDNF elevation study (Zh Nevrol Psikhiatr, 2018).
3. Dolotov OV et al. Dopamine/serotonin turnover in frontal cortex and hippocampus (Neurochem Res, 2003).
4. Medvedeva EV et al. Anti-inflammatory cytokine shift in acute stroke (BMC Genomics, 2014).
5. Shmonin AA et al. Meta-analysis of Russian acute stroke trials (Vestnik Vosstanovitel'noy Meditsiny, 2018).
6. Potaman VN et al. Enkephalinase inhibition by Semax (Dokl Biochem Biophys, 2001).